JP7712271B2 - アデノ随伴ウイルスベクター変種 - Google Patents

アデノ随伴ウイルスベクター変種

Info

Publication number
JP7712271B2
JP7712271B2 JP2022529681A JP2022529681A JP7712271B2 JP 7712271 B2 JP7712271 B2 JP 7712271B2 JP 2022529681 A JP2022529681 A JP 2022529681A JP 2022529681 A JP2022529681 A JP 2022529681A JP 7712271 B2 JP7712271 B2 JP 7712271B2
Authority
JP
Japan
Prior art keywords
capsid protein
modified
present
targeting peptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022529681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503455A (ja
JP2023503455A5 (https=
Inventor
ビバリー デイビッドソン
ヨンホン チェン
ポール ティー． ラナム
シュエユアン リュウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of JP2023503455A publication Critical patent/JP2023503455A/ja
Publication of JP2023503455A5 publication Critical patent/JP2023503455A5/ja
Priority to JP2025044678A priority Critical patent/JP2025102825A/ja
Priority to JP2025116303A priority patent/JP2025148448A/ja
Application granted granted Critical
Publication of JP7712271B2 publication Critical patent/JP7712271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022529681A 2019-11-22 2020-11-20 アデノ随伴ウイルスベクター変種 Active JP7712271B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025044678A JP2025102825A (ja) 2019-11-22 2025-03-19 アデノ随伴ウイルスベクター変種
JP2025116303A JP2025148448A (ja) 2019-11-22 2025-07-10 アデノ随伴ウイルスベクター変種

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962939315P 2019-11-22 2019-11-22
US62/939,315 2019-11-22
US202063084709P 2020-09-29 2020-09-29
US63/084,709 2020-09-29
PCT/US2020/061464 WO2021102234A1 (en) 2019-11-22 2020-11-20 Adeno-associated viral vector variants

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025044678A Division JP2025102825A (ja) 2019-11-22 2025-03-19 アデノ随伴ウイルスベクター変種
JP2025116303A Division JP2025148448A (ja) 2019-11-22 2025-07-10 アデノ随伴ウイルスベクター変種

Publications (3)

Publication Number Publication Date
JP2023503455A JP2023503455A (ja) 2023-01-30
JP2023503455A5 JP2023503455A5 (https=) 2024-01-30
JP7712271B2 true JP7712271B2 (ja) 2025-07-23

Family

ID=75980202

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022529681A Active JP7712271B2 (ja) 2019-11-22 2020-11-20 アデノ随伴ウイルスベクター変種
JP2025044678A Pending JP2025102825A (ja) 2019-11-22 2025-03-19 アデノ随伴ウイルスベクター変種
JP2025116303A Pending JP2025148448A (ja) 2019-11-22 2025-07-10 アデノ随伴ウイルスベクター変種

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025044678A Pending JP2025102825A (ja) 2019-11-22 2025-03-19 アデノ随伴ウイルスベクター変種
JP2025116303A Pending JP2025148448A (ja) 2019-11-22 2025-07-10 アデノ随伴ウイルスベクター変種

Country Status (13)

Country Link
US (2) US20230346981A1 (https=)
EP (1) EP4061427A4 (https=)
JP (3) JP7712271B2 (https=)
KR (1) KR20220116459A (https=)
CN (2) CN115023242B (https=)
AU (1) AU2020388404A1 (https=)
BR (1) BR112022009864A2 (https=)
CA (1) CA3159113A1 (https=)
CO (1) CO2022008507A2 (https=)
IL (1) IL293140A (https=)
MX (1) MX2022006188A (https=)
PH (1) PH12022551247A1 (https=)
WO (1) WO2021102234A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4136457B1 (en) * 2020-04-17 2025-02-19 Regeneron Pharmaceuticals, Inc. Detection assays for coronavirus neutralizing antibodies
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
JP2025514794A (ja) * 2022-04-22 2025-05-09 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア ヒト上衣特異的プロモーターおよびその使用方法
CN119654334A (zh) * 2022-05-11 2025-03-18 费城儿童医院 用于靶向深层脑结构的腺相关病毒载体
AU2023267671A1 (en) * 2022-05-13 2024-12-05 The Children's Hospital Of Philadelphia Adeno-associated viral vectors for targeting brain microvasculature
JP2025521111A (ja) 2022-05-16 2025-07-08 ジェンザイム・コーポレーション 異染性白質ジストロフィーを治療する方法
WO2024017387A1 (en) 2022-07-22 2024-01-25 Shanghai Vitalgen Biopharma Co., Ltd. Novel aav capsids for targeting nervous system and uses thereof
KR102870168B1 (ko) * 2022-08-26 2025-10-13 김선아 활막 표적화 화합물 및 이의 용도
IL319666A (en) * 2022-09-19 2025-05-01 Childrens Hospital Philadelphia AV evolution at single-cell resolution using SPLIT-SEQ
IL322459A (en) * 2023-01-31 2025-09-01 Childrens Hospital Philadelphia Innovative gene therapy construct for cln2 disease
WO2024191778A1 (en) 2023-03-10 2024-09-19 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
CN116970041B (zh) * 2023-07-21 2024-02-09 广州派真生物技术有限公司 腺相关病毒突变体及其应用
AU2024332181A1 (en) 2023-08-31 2026-02-12 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2025090598A1 (en) * 2023-10-23 2025-05-01 The Children's Hospital Of Philadelphia Aav vectors for treatment of cln2 disease
WO2025090631A1 (en) * 2023-10-23 2025-05-01 The Children's Hospital Of Philadelphia Aav vectors for delivery of apoe2
US20250152747A1 (en) * 2023-11-15 2025-05-15 Genzyme Corporation Methods of treating gaucher disease and gba-parkinson’s disease
US20250152744A1 (en) * 2023-11-15 2025-05-15 Genzyme Corporation Methods of treating neurodegenerative disorders
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2025213097A1 (en) * 2024-04-05 2025-10-09 The Children's Hospital Of Philadelphia Novel gene therapy constructs for stxbp1 haploinsufficiency
WO2025231406A1 (en) * 2024-05-02 2025-11-06 The Children's Hospital Of Philadelphia Methods to increase transduction of ependyma cells in brain
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
CN121265801A (zh) * 2025-06-06 2026-01-06 昆明理工大学 一种靶向性的药物递送载体及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513486A (ja) 2014-04-17 2017-06-01 ウニヴェルズィテーツクリニクム ハンブルク−エッペンドルフＵｎｉｖｅｒｓｉｔａｅｔｓｋｌｉｎｉｋｕｍ Ｈａｍｂｕｒｇ−Ｅｐｐｅｎｄｏｒｆ 脳および脊髄に標的化遺伝子移入するためのウイルスベクター
JP2019506141A (ja) 2015-12-11 2019-03-07 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）を誘導するための標的指向性ペプチド

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
PT1453547T (pt) * 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
ES2739288T3 (es) * 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
US11905312B2 (en) * 2017-02-15 2024-02-20 The University Of North Carolina At Chapel Hill Methods and compositions for gene transfer across the vasculature
RU2019140862A (ru) * 2017-05-12 2021-06-15 Дзе Чилдрен'З Хоспитал Оф Филадельфия Варианты сульфамидазы (sgsh), векторы, композиции и способы, и применения для лечения мукополисахаридоз типа iiia (mps iiia)
RU2770922C2 (ru) * 2017-09-20 2022-04-25 4Д Молекьюлар Терапьютикс Инк. Капсиды вариантов аденоассоциированных вирусов и методы их применения
AU2018338728B2 (en) * 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
WO2019113538A2 (en) * 2017-12-07 2019-06-13 California Institute Of Technology Methods and systems for noninvasive control of brain cells and related vectors and compositions
WO2019222329A1 (en) * 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2020014471A1 (en) * 2018-07-11 2020-01-16 The Brigham And Women's Hospital, Inc. Methods and compositions for delivery of agents across the blood-brain barrier

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513486A (ja) 2014-04-17 2017-06-01 ウニヴェルズィテーツクリニクム ハンブルク−エッペンドルフＵｎｉｖｅｒｓｉｔａｅｔｓｋｌｉｎｉｋｕｍ Ｈａｍｂｕｒｇ−Ｅｐｐｅｎｄｏｒｆ 脳および脊髄に標的化遺伝子移入するためのウイルスベクター
JP2019506141A (ja) 2015-12-11 2019-03-07 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）を誘導するための標的指向性ペプチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nat. Biotechnol.，2016年，Vol. 34, No. 2，p. 204-209

Also Published As

Publication number Publication date
JP2025102825A (ja) 2025-07-08
CA3159113A1 (en) 2021-05-27
JP2023503455A (ja) 2023-01-30
KR20220116459A (ko) 2022-08-23
PH12022551247A1 (en) 2023-11-13
EP4061427A1 (en) 2022-09-28
WO2021102234A1 (en) 2021-05-27
MX2022006188A (es) 2022-08-22
BR112022009864A2 (pt) 2022-08-02
CN119978146A (zh) 2025-05-13
JP2025148448A (ja) 2025-10-07
CN115023242A (zh) 2022-09-06
CO2022008507A2 (es) 2022-07-08
EP4061427A4 (en) 2024-01-10
IL293140A (en) 2022-07-01
US20230346981A1 (en) 2023-11-02
CN115023242B (zh) 2025-03-14
US20240100194A1 (en) 2024-03-28
AU2020388404A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JP7712271B2 (ja) アデノ随伴ウイルスベクター変種
US20250019669A1 (en) Cell lines with improved aav production capacity
KR20250031153A (ko) 뇌 심부 구조를 표적화하기 위한 아데노-관련 바이러스 벡터
US20240197920A1 (en) Adeno-associated viral vectors for transduction of cochlea
US20220098614A1 (en) Compositions and Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD)
RU2845941C1 (ru) Варианты аденоассоциированного вирусного вектора
US20250312399A1 (en) Adeno-associated viral vectors for targeting brain microvasculature
US20250269064A1 (en) Human ependyma-specific promoter and uses thereof
WO2025231387A1 (en) Globus pallidus route of administration for deep brain gene therapies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250710

R150 Certificate of patent or registration of utility model

Ref document number: 7712271

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150